{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:26:29Z","timestamp":1764239189123},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1053\/j.semnephrol.2003.08.018","type":"journal-article","created":{"date-parts":[[2004,1,16]],"date-time":"2004-01-16T20:45:36Z","timestamp":1074285936000},"page":"10-16","source":"Crossref","is-referenced-by-count":45,"title":["Vitamin D receptor and analogs"],"prefix":"10.1016","volume":"24","author":[{"given":"Adriana S","family":"Dusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Slatopolsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnephrol.2003.08.018_BIB1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB2","first-page":"F157","article-title":"Vitamin D","volume":"277","author":"Brown","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB3","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1523-1755.2001.059003855.x","article-title":"p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth","volume":"59","author":"Dusso","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/oxfordjournals.ndt.a027131","article-title":"De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism","volume":"11","author":"Gogusev","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB6","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1046\/j.1523-1755.2001.00042.x","article-title":"p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium","volume":"60","author":"Cozzolino","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB7","first-page":"193A","article-title":"Specific inhibition of EGFR-signaling prevents high phosphorus-induced parathyroid hyperplasia in renal failure","volume":"13","author":"Cozzolino","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB8","doi-asserted-by":"crossref","first-page":"38965","DOI":"10.1074\/jbc.M203736200","article-title":"1,25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor","volume":"277","author":"Cordero","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB9","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1046\/j.1523-1755.1999.00396.x","article-title":"Expression of PRAD1\/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma","volume":"55","author":"Tominaga","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB10","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1523-1755.2002.kid585.x","article-title":"Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism","volume":"62","author":"Tokumoto","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0092-8674(00)80655-8","article-title":"An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3","volume":"96","author":"Nykjaer","year":"1999","journal-title":"Cell"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1010062929140","article-title":"Molecular nature of the vitamin D receptor and its role in regulation of gene expression","volume":"2","author":"Jurutka","year":"2001","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0955-0674(00)00209-X","article-title":"Mediator complexes and transcription","volume":"13","author":"Rachez","year":"2001","journal-title":"Curr Opin Cell Biol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-1119(00)00052-4","article-title":"Mechanisms of gene regulation by vitamin D(3) receptor","volume":"246","author":"Rachez","year":"2000","journal-title":"Gene"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB15","doi-asserted-by":"crossref","first-page":"20082","DOI":"10.1016\/S0021-9258(19)88668-4","article-title":"Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization","volume":"267","author":"Wiese","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.1996.283","article-title":"1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats","volume":"50","author":"Denda","year":"1996","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1681\/ASN.V82271","article-title":"Secondary hyperparathyroidism and vitamin D receptor binding to vitamin D response elements in rats with incipient renal failure","volume":"8","author":"Sawaya","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI118061","article-title":"Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins","volume":"96","author":"Patel","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB19","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1210\/me.12.8.1193","article-title":"Calreticulin inhibits vitamin D\u2019s action on the PTH gene in vitro and may prevent vitamin D\u2019s effect in vivo in hypocalcemic rats","volume":"12","author":"Sela-Brown","year":"1998","journal-title":"Mol Endocrinol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB20","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1128\/MCB.22.8.2777-2787.2002","article-title":"Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription","volume":"22","author":"Vidal","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/MCB.19.2.1049","article-title":"Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog","volume":"19","author":"Takeyama","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB22","first-page":"S433","article-title":"Interactions of VDR with co-regulators by new vitamin D analogs","volume":"16","author":"Takeyama","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1 alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB24","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats","volume":"114","author":"Sjoden","year":"1984","journal-title":"J Nutr"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB25","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1210\/en.136.11.4749","article-title":"Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D3 in rats and monkeys","volume":"136","author":"Knutson","year":"1995","journal-title":"Endocrinology"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB26","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/jc.83.6.2156","article-title":"Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans","volume":"83","author":"Mawer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(01)80010-X","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3177\/jnsv.35.529","article-title":"Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3","volume":"35","author":"Okano","year":"1989","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB31","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo-128-4-1687","article-title":"On the mechanisms for the selective action of vitamin D analogs","volume":"128","author":"Dusso","year":"1991","journal-title":"Endocrinology"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1172\/JCI114229","article-title":"The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion","volume":"84","author":"Brown","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(00)70198-3","article-title":"Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism","volume":"35","author":"Tsukamoto","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB34","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1523-1755.1999.055003821.x","article-title":"22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure","volume":"55","author":"Monier-Faugere","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB36","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB37","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1523-1755.2002.kid573.x","article-title":"Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats","volume":"62","author":"Slatopolsky","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB39","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB40","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.semnephrol.2003.08.018_BIB41","first-page":"461A","article-title":"Survival benefit of Zemplar compared with calcijex among dialysis patients","volume":"13","author":"Teng","year":"2002","journal-title":"J Am Soc Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929503001475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929503001475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T01:02:34Z","timestamp":1623632554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929503001475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0270929503001475"],"URL":"https:\/\/doi.org\/10.1053\/j.semnephrol.2003.08.018","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}